Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 6/20 | 0.33 |
| ▸ | CA1 | P00915 | 6/20 | 0.33 |
| ▸ | CA2 | P00918 | 6/20 | 0.33 |
| ▸ | CA9 | Q16790 | 6/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578390 | 1.00 | CD44 (0.36) | CD44TSHRSCN4ACA12CA1 | |
| SCHEMBL23752486 | 0.95 | CD44 (0.36) | CD44TSHRSCN4ACA12CA1 | |
| SCHEMBL5578381 | 0.82 | CNR1 (0.36) | SCN4ACA12CA1CA2CA9 | |
| SCHEMBL5578853 | 0.81 | ALDH1A1 (0.38) | TSHRKMT2AROCK2 | |
| SCHEMBL5578542 | 0.79 | MAPT (0.42) | TSHRSCN4AHCRTR1HCRTR2 | |
| SCHEMBL5578520 | 0.78 | TP53 (0.39) | KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL4609720 | 0.78 | DRD2 (0.33) | ROCK2HTR2C | |
| SCHEMBL5578398 | 0.78 | DRD2 (0.33) | ROCK2HTR2C | |
| SCHEMBL28305429 | 0.77 | AAK1 (0.34) | SCN4A | |
| SCHEMBL5578280 | 0.75 | CA1 (0.41) | CA1CA2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | WYETH | 2007-09-27 | — | — | US | claimed |
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | WYETH | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | HCCS, HAVCR2, SULT2A1 | CD44 1762/4885TSHR 670/4885SCN4A 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.